BS group (n=81) | AG group (n=39) | AS group (n=38) | Total (n=158) | p Value | |
---|---|---|---|---|---|
Primary endpoints | |||||
Successful PTAS (n (%)) | 79 (97.5) | 35 (89.7) | 38 (100.0) | 152 (96.2) | 0.042 |
Secondary endpoints | |||||
Any stroke or death | 4 (4.9) | 0 (0.0) | 3 (7.9) | 7 (4.4) | 0.231 |
Any ischemic stroke | 4 (4.9) | 0 (0.0) | 2 (5.3) | 6 (3.8) | 0.359 |
Any hemorrhagic stroke | 0 (0.0) | 0 (0.0) | 1 (2.4) | 1 (0.6) | 0.204 |
Death | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
MI | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
SAE | 0 (0.0) | 0 (0.0) | 1 (2.4) | 0 (0.6) | 0.204 |
mRS≥3 | 2 (2.5) | 0 (0.0) | 2 (5.3) | 4 (2.5) | 0.339 |
AG group, angioplasty group; AS group, angioplasty plus self-expanding stent group; BS group, balloon mounted stent group; MI, myocardial infarction; mRS, modified Rankin Scale; PTAS, percutaneous transluminal angioplasty and stenting; SAE, serious adverse event.